Goto Hiromasa, Mita Tomoya, Fujitani Yoshio, Fujimoto Shimpei, Takahashi Kiyohito, Satoh Hiroaki, Hirose Takahisa, Hiyoshi Toru, Ai Masumi, Okada Yosuke, Nishimura Hideki, Kuroda Hisamoto, Matsubara Toshiki, Gosho Masahiko, Ishii Hitoshi, Watada Hirotaka
Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Laboratory of Developmental Biology and Metabolism, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
Endocr J. 2018 Jun 27;65(6):657-668. doi: 10.1507/endocrj.EJ18-0088. Epub 2018 Apr 10.
Treatment-related quality of life (QOL) is an important aspect of diabetes management. However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus alpha-glucosidase inhibitors on treatment-related QOL. This prespecified sub-analysis of the Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) compared the effects of linagliptin (5 mg once daily) and voglibose (0.2 mg/meal thrice daily) on treatment-related QOL in Japanese patients with type 2 diabetes (T2DM) inadequately controlled with diet and exercise therapy. Among 366 subjects in the original study, 182 in the linagliptin group and 173 in the voglibose group were included in this analysis. The outcome of this study was change in QOL as assessed by the Diabetes Therapy-Related Quality of Life 17 (DTR-QOL17) questionnaire from baseline to week 12. Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment. The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group. In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score. Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM.
治疗相关生活质量（QOL）是糖尿病管理的一个重要方面。然而，尚无研究比较二肽基肽酶-4抑制剂与α-葡萄糖苷酶抑制剂对治疗相关生活质量的影响。这项对利格列汀餐后血糖效应研究（L-STEP）的预先设定的亚组分析，比较了利格列汀（每日一次，每次5毫克）和伏格列波糖（每餐0.2毫克，每日三次）对饮食和运动疗法控制不佳的日本2型糖尿病（T2DM）患者治疗相关生活质量的影响。在原研究的366名受试者中，本分析纳入了利格列汀组的182名和伏格列波糖组的173名。本研究的结果是通过糖尿病治疗相关生活质量17（DTR-QOL17）问卷评估的从基线到第12周生活质量的变化。与基线数据相比，利格列汀和伏格列波糖治疗12周后，DTR-QOL17总分显著更高。利格列汀组的DTR-QOL17总分变化以及一个领域（社交活动和日常活动负担）的得分变化显著大于伏格列波糖组。此外，仅利格列汀治疗被确定为与DTR-QOL17总分增加相关的因素。在改善饮食和运动疗法控制不佳的日本T2DM患者治疗相关生活质量方面，利格列汀优于伏格列波糖。
